Tumor necrosis factor alpha-induced protein 8 (TNFAIP8)

Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) is a cytoplasmic and nucleoplasmic protein containing a death effector domain (DED) that acts as a negative regulator of apoptosis, primarily by inhibiting caspase-8 activity and thereby blocking the progression of programmed cell death[3][6]. TNFAIP8 is a key member of the TIPE family, widely expressed in immune organs, gastrointestinal tissues, and various other tissues, and is implicated in the modulation of inflammatory and immune responses[1][5]. TNFAIP8 is frequently overexpressed in many cancers—where it can promote proliferation, invasion, metastasis, and resistance to apoptosis—yet in some contexts it may exert tumor suppressor functions, particularly in inflammation-associated carcinogenesis of the intestinal tract[1][2][5]. High TNFAIP8 expression in tumors is generally predictive of poor prognosis, metastasis, and drug resistance, while in some cancers (e.g., skin melanoma), low expression is associated with worse outcomes[4][5]. As a biomarker, TNFAIP8 levels are considered prognostic and may inform patient selection or therapeutic strategies targeting apoptotic pathways or inflammation in malignancy and immune-related diseases[2][4][5].

Other names

TIPENDEDGG2-1MDC-3.13SCC-S2Head and neck tumor and metastasis-related proteinNF-kappa-B-inducible DED-containing proteinTNF-induced protein GG2-1

For drugs like cisplatin: TNFAIP8 modulates resistance by inhibiting apoptosis and enhancing DNA repair processes, thereby promoting cell proliferation and drug resistance in tumor cells[8]. Inhibition or silencing of TNFAIP8 reactivates apoptosis (via caspase-3/8 activation), cell cycle arrest, and decreases proliferation[2][8].